{
    "organizations": [],
    "uuid": "0a600121fabd17df8ab151300f8552bf5a98c2e5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-immunovia-signs-loi-with-dd2-cente/brief-immunovia-signs-loi-with-dd2-center-idUSASM000I1L",
    "ord_in_thread": 0,
    "title": "BRIEF-Immunovia Signs LoI With DD2 Center",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 11 (Reuters) - IMMUNOVIA AB (PUBL):\n* ‍SIGNED A LETTER OF INTENT FOR COLLABORATION WITH DANISH CENTER FOR STRATEGIC RESEARCH INTO TYPE 2 DIABETES​\n* ‍INTENTION IS DD2 CENTER WILL BE PART OF GROUNDBREAKING PANDIA-1 PROSPECTIVE STUDY INTO NEW ONSET TYPE 2 DIABETICS​\n* IMMUNOVIA ACCELERATES PANCREAS CANCER STUDY OF NEW ONSET DIABETICS BY ADDING DENMARK‘S DIABETES CENTER FOR STRATEGIC RESEARCH-DD2 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-01-11T21:33:00.000+02:00",
    "crawled": "2018-01-12T18:36:08.094+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "immunovia",
        "ab",
        "publ",
        "letter",
        "intent",
        "collaboration",
        "danish",
        "center",
        "strategic",
        "research",
        "type",
        "dd2",
        "center",
        "part",
        "groundbreaking",
        "prospective",
        "study",
        "new",
        "onset",
        "type",
        "immunovia",
        "accelerates",
        "pancreas",
        "cancer",
        "study",
        "new",
        "onset",
        "diabetic",
        "adding",
        "denmark",
        "diabetes",
        "center",
        "strategic",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}